CTU: 78278343PCR1003 A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer

  • Crumbaker, Megan (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title78278343PCR1003
StatusActive
Effective start/end date14/07/23 → 24/05/28